---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-001644"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-08-28T23:59:59+00:00"
generated_at: "2026-06-11T02:49:37.141769+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lexaria regains Nasdaq minimum bid price compliance; plans reverse split meeting

## Summary
- Received Nasdaq letter confirming bid price >=$1.00 for 10 consecutive days through Aug 23, 2023.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing.
- Company called special meeting to approve possible reverse stock split by May 31, 2024.
- Intends to proceed with reverse split proposal to enable quick future compliance and attract investment.

## SEC filing metadata
- accession: 0001640334-23-001644
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-08-28T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/0001640334-23-001644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-001644
- JSON: https://secwatch.observer/filing/0001640334-23-001644.json
- Plain text: https://secwatch.observer/filing/0001640334-23-001644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.